Cambrex Acquires Biopharmaceutical Producer
The 65,000 square foot facility contains two fully validated suites dedicated to various biologic processes and adequate space for three additional cGMP suites. The US FDA has successfully inspected the existing suites. Current production capabilities include bacterial and yeast fermentation units up to a capacity of 800 liters, small and large-scale purification, and a 1500+ vial filling facility for Phase I and Phase II clinical trials. Full year 2001 sales revenues are targeted at approximately $8.5 million. Sales revenues in 2002 are expected to grow in excess of 50%.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.